Cargando…

Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia

Type 2 diabetic mellitus is a multifactorial metabolic disorder affecting huge population around the world. This indicates that there is an urgent unmet need of cost effective, new treatment strategies for type 2 diabetes mellitus with no or less side effects. Phenolic compounds including isoflavone...

Descripción completa

Detalles Bibliográficos
Autores principales: Oza, Manisha J., Kulkarni, Yogesh A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058024/
https://www.ncbi.nlm.nih.gov/pubmed/30072892
http://dx.doi.org/10.3389/fphar.2018.00739
_version_ 1783341619583385600
author Oza, Manisha J.
Kulkarni, Yogesh A.
author_facet Oza, Manisha J.
Kulkarni, Yogesh A.
author_sort Oza, Manisha J.
collection PubMed
description Type 2 diabetic mellitus is a multifactorial metabolic disorder affecting huge population around the world. This indicates that there is an urgent unmet need of cost effective, new treatment strategies for type 2 diabetes mellitus with no or less side effects. Phenolic compounds including isoflavones are known for their beneficial effect in metabolic disorders. The present work was intended to find out efficacy of formononetin, an isoflavone treatment in experimental model of type 2 diabetes. Type 2 diabetes mellitus was induced by feeding high fat diet for 2 weeks prior to streptozotocin administration in Sprague Dawley rats. Diabetic animals were treated with formononetin for 28 days at three dose level, i.e., 10, 20, and 40 mg/kg body weight orally. The effect of formononetin treatment on various parameters such as plasma glucose, glucose tolerance, insulin, HOMA-IR, lipid profile, hepatic glycogen content, glycohaemoglobin and SIRT1 expression in pancreatic tissue was measured. Histopathological changes in pancreatic tissue were also studied. Results of the study demonstrate that formononetin treatment reduces blood glucose level significantly (p < 0.001) at all the three dose level. It also improved glucose tolerance, insulin sensitivity and lipid profile along with reduction in glycohaemoglobin content in blood. Formononetin treatment also improved hepatic glycogen level profoundly in diabetic rats. Determination of SIRT1 expression in pancreatic tissue by immunohistochemical analysis showed that formononetin treatment increases the expression of SIRT1 in pancreatic tissue. Histopathological study showed that treatment with formononetin protects pancreatic beta cells from necro-degeneration and atrophic effect. It can be concluded that formononetin treatment reduces insulin resistance and attenuate hyperglycemia in type 2 diabetes which may be due to increasing expression of SIRT1 in pancreatic tissues.
format Online
Article
Text
id pubmed-6058024
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-60580242018-08-02 Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia Oza, Manisha J. Kulkarni, Yogesh A. Front Pharmacol Pharmacology Type 2 diabetic mellitus is a multifactorial metabolic disorder affecting huge population around the world. This indicates that there is an urgent unmet need of cost effective, new treatment strategies for type 2 diabetes mellitus with no or less side effects. Phenolic compounds including isoflavones are known for their beneficial effect in metabolic disorders. The present work was intended to find out efficacy of formononetin, an isoflavone treatment in experimental model of type 2 diabetes. Type 2 diabetes mellitus was induced by feeding high fat diet for 2 weeks prior to streptozotocin administration in Sprague Dawley rats. Diabetic animals were treated with formononetin for 28 days at three dose level, i.e., 10, 20, and 40 mg/kg body weight orally. The effect of formononetin treatment on various parameters such as plasma glucose, glucose tolerance, insulin, HOMA-IR, lipid profile, hepatic glycogen content, glycohaemoglobin and SIRT1 expression in pancreatic tissue was measured. Histopathological changes in pancreatic tissue were also studied. Results of the study demonstrate that formononetin treatment reduces blood glucose level significantly (p < 0.001) at all the three dose level. It also improved glucose tolerance, insulin sensitivity and lipid profile along with reduction in glycohaemoglobin content in blood. Formononetin treatment also improved hepatic glycogen level profoundly in diabetic rats. Determination of SIRT1 expression in pancreatic tissue by immunohistochemical analysis showed that formononetin treatment increases the expression of SIRT1 in pancreatic tissue. Histopathological study showed that treatment with formononetin protects pancreatic beta cells from necro-degeneration and atrophic effect. It can be concluded that formononetin treatment reduces insulin resistance and attenuate hyperglycemia in type 2 diabetes which may be due to increasing expression of SIRT1 in pancreatic tissues. Frontiers Media S.A. 2018-07-18 /pmc/articles/PMC6058024/ /pubmed/30072892 http://dx.doi.org/10.3389/fphar.2018.00739 Text en Copyright © 2018 Oza and Kulkarni. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Oza, Manisha J.
Kulkarni, Yogesh A.
Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title_full Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title_fullStr Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title_full_unstemmed Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title_short Formononetin Treatment in Type 2 Diabetic Rats Reduces Insulin Resistance and Hyperglycemia
title_sort formononetin treatment in type 2 diabetic rats reduces insulin resistance and hyperglycemia
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058024/
https://www.ncbi.nlm.nih.gov/pubmed/30072892
http://dx.doi.org/10.3389/fphar.2018.00739
work_keys_str_mv AT ozamanishaj formononetintreatmentintype2diabeticratsreducesinsulinresistanceandhyperglycemia
AT kulkarniyogesha formononetintreatmentintype2diabeticratsreducesinsulinresistanceandhyperglycemia